CYP Closes $15m Institutional Placement to Expand Pipeline
Filed with ASX · · 4 pages · English
Cynata Therapeutics Limited on 6ix
In the deck
Earlier from Cynata Therapeutics
- Cynata Therapeutics: Phase 3 Osteoarthritis Clinical Trial Commences
- Potential Utility of Cymerus MSCs in Heart Attack Model
- Cymerus MSCs Demonstrate Efficacy in Preclinical Lung Disease Study
- Cymerus MSCs Effective in Preclinical Lung Disease Study
- Patient Enrolment Opens in COVID-19 Clinical Trial
Later from Cynata Therapeutics
- Investor Presentation
- Cynata Therapeutics Secures $15m Placement Led By $10m from Healthcare Investor BioScience Managers to Expand Development Pipeline
- Offer Booklet and Entitlement & Acceptance Form
- Completion of Entitlement Offer and Shortfall Placement
- Cynata Receives $1.39m R&D Tax Incentive Refund
Follow Cynata Therapeutics into a list and get an email when it puts out news.
Follow Cynata Therapeutics